Advertisement

Drugs, driving and traffic safety in allergic rhinitis

  • Eef Lien Theunissen
  • Annemiek Vermeeren
  • Eric F. P. M. Vuurman
  • Johannes G. Ramaekers

Abstract

Antihistamines are used as a treatment for allergies but cause sedation as a side effect. This sedation can be so severe that it interferes with patients daily functioning such as driving a vehicle. This chapter gives an overview of the effects of numerous antihistamines on driving performance as assessed in a standard highway driving test. When investigating the effects of an acute administration of the therapeutic dose, many antihistamines cause driving impairment comparable or larger than the effect of 0,5 mg/ml alcohol (i.e. hydroxizine, emedastine, diphenhydramine, clemastine, triprolidine, mizolastine, mequitazine, dexchlorpheniramine CR). However this does not mean that the other antihistamines are free of sedating effects. Driving impairment has been demonstrated for most antihistamines after increased or repeated doses. Also women often appeared to be more sensitive for the sedating effects of antihistamines. So far, only a few antihistamines appear to be free of impairing effects on driving (i.e. desloratadine, levocetirizine, fexofenadine and rupatadine), however, not all have them have been tested after higher or repeated dosing. This review of more than 15 driving studies indicates that most antihistamines have the potential to impair performance. Therefore patients should be correctly advised and informed about the possible risks when choosing a treatment.

Keywords

Allergic Rhinitis Subchronic Effect EAACI Position Paper KDYH DOVR GLIIHUHQW IURP 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steerenberg PA, van Loveren H, Vandebriel FJ, Vos JG, Opperhuizen A, van Amsterdam JGC (2000) The prevalence of asthma and allergy increases: a world-wide problem. Rijksinstituut voor volksgezondheid en milieu, Bilthoven, 1–30Google Scholar
  2. 2.
    Nathan RA, Meltzer EO, Selner JC, Storms W (1997) Prevalence of allergic rhinitis in the United States. Journal of Allergy and Clinical Immunology 99: S808–S814CrossRefGoogle Scholar
  3. 3.
    Snyder SH, Snowman AM (1987) Receptor effects of cetirizine. Ann Allergy 59: 4–8PubMedGoogle Scholar
  4. 4.
    Simons FE (1989) H1-receptor antagonists: clinical pharmacology and therapeutics. Journal of Allergy and Clinical Immunology 84: 845–861PubMedCrossRefGoogle Scholar
  5. 5.
    Golightly LK, Greos LS (2005) Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 65: 341–384PubMedCrossRefGoogle Scholar
  6. 6.
    Simons FE, Simons KJ, Chung M, Yeh J (1987) The comparative pharmacokinetics of H1-receptor antagonists. Ann Allergy 59: 20–24.PubMedGoogle Scholar
  7. 7.
    Gonzalez MA, Estes KS (1998) Pharmacokinetic overview of oral second-generation H1 antihistamines. International Journal of Clinical Pharmacology and Therapeutics 36: 292–300PubMedGoogle Scholar
  8. 8.
    Slater JW, Zechnich AD, Haxby DG (1999) Second-generation antihistamines: a comparative review. Drugs 57: 31–47PubMedCrossRefGoogle Scholar
  9. 9.
    Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, Mercer AD (1991) Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. British Journal of Pharmacology 104: 270–276PubMedGoogle Scholar
  10. 10.
    Quach TT, Duchemin AM, Rose C, Schwartz JC (1979) In vivo occupation of cerebral histamine H1-receptors evaluated with 3H-mepyramine may predict sedative properties of psychotropic drugs. European Journal of Pharmacology 60: 391–392PubMedCrossRefGoogle Scholar
  11. 11.
    Rose C, Quach TT, Llorens C, Schwartz JC (1982) Relationship between occupation of cerebral H1-receptors and sedative properties of antihistamines. Assessment in the case of terfenadine. Arzneimittel Forschung 32: 1171–1173PubMedGoogle Scholar
  12. 12.
    Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S et al (2001) Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. British Journal of Clinical Pharmacology 52: 501–509PubMedCrossRefGoogle Scholar
  13. 13.
    Tashiro M, Mochizuki H, Iwabuchi K, Sakurada Y, Itoh M, Watanabe T, Yanai K (2002) Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sciences 72: 409–414PubMedCrossRefGoogle Scholar
  14. 14.
    Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW (2001) The impact of allergies and allergy treatment on worker productivity. Journal of Occupational and Environmental Medicine 43: 64–71PubMedCrossRefGoogle Scholar
  15. 15.
    McLoughlin J, Nall M, Isaacs B, Petrosko J, Karibo J, Lindsey B (1983) The relationship of allergies and allergy treatment to school performance and student behavior. Annals of Allergy 51: 506–510PubMedGoogle Scholar
  16. 16.
    McMenamin P (1994) Costs of hay fever in the United States in 1990. Annals of Allergy 73: 35–39PubMedGoogle Scholar
  17. 17.
    Cimbura G, Lucas DM, Bennett RC, Warren RA, Simpson HM (1982) Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. Journal of Forensic Sciences 27: 855–867PubMedGoogle Scholar
  18. 18.
    Ray WA, Fought RL, Decker MD (1992) Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. American Journal of Epidemiology 136: 873–883.PubMedCrossRefGoogle Scholar
  19. 19.
    Leveille SG, Buchner DM, Koepsell TD, McCloskey LW, Wolf ME, Wagner EH (1994) Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 5: 591–598.PubMedCrossRefGoogle Scholar
  20. 20.
    Gilmore TM, Alexander BH, Mueller BA, Rivara FP (1996) Occupational injuries and medication use. American Journal of Industrial Medicine 30: 234–239PubMedCrossRefGoogle Scholar
  21. 21.
    Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F et al (1996) The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy 51: 666–675PubMedGoogle Scholar
  22. 22.
    Mann RD, Pearce GL, Dunn N, Shakir S (2000) Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice. British Medical Journal 320: 1184–1186.PubMedCrossRefGoogle Scholar
  23. 23.
    Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Simons FE, Spangler DL, Szefler SJ, Terndrup TE et al (2003) First do no harm: managing antihistamine impairment in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology 111: S835–842PubMedCrossRefGoogle Scholar
  24. 24.
    Vermeeren A, Ramaekers JG, O’Hanlon JF (2002) Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. Journal of Psychopharmacology 16: 57–64PubMedCrossRefGoogle Scholar
  25. 25.
    Vuurman EF, Theunissen EL, Oers ACM, Leeuwen, Jolles J (2007) Lack of effects between rupatadine 10mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacology 22: 289–297PubMedCrossRefGoogle Scholar
  26. 26.
    Ramaekers JG, O’Hanlon JF (1994) Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. European Journal of Clinical Pharmacology 47: 261–266PubMedCrossRefGoogle Scholar
  27. 27.
    Vuurman EFPM, Rikken GH, Muntjewerff ND, de Halleux F, Ramaekers JG (2004) Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. European Journal of Clinical Pharmacology 60: 307–313PubMedCrossRefGoogle Scholar
  28. 28.
    Verster JC, de Weert AM, Bijtjes SI, Aarab M, van Oosterwijck AW, Eijken EJ, Verbaten MN, Volkerts ER (2003) Driving ability after acute and sub-chronic administration of le vocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 169: 84–90PubMedCrossRefGoogle Scholar
  29. 29.
    Vuurman EF, Uiterwijk MM, Rosenzweig P, O’Hanlon JF (1994) Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. European Journal of Clinical Pharmacology 47: 253–259PubMedCrossRefGoogle Scholar
  30. 30.
    Vermeeren A, O’Hanlon JF (1998) Fexofenadine’s effects, alone and with alcohol, on actual driving and psychomotor performance. Journal of Allergy and Clinical Immunology 101: 306–311PubMedCrossRefGoogle Scholar
  31. 31.
    Volkerts ER, Van Willigenburg AP, Van Laar MW, Maes RA (1992) Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Human Psychopharmacology Clinical and Experimental 7: 227–238CrossRefGoogle Scholar
  32. 32.
    Robbe HWJ, O’Hanlon JF (1990) Effects of acrivastine, acrivastine plus pseudoephedrine and triprolidine on highway driving. Institute for Drugs, Safety and Behavior University of Limburg, MaastrichtGoogle Scholar
  33. 33.
    Riedel WJ, Ramaekers G, Uiterwijk MM, O’Hanlon JF (1990) Higher doses of terfenadine and loratadine: acute and subchronic effects on psychomotor and actual driving performance. Institute for Drugs, Safety and Behavior, University of Limburg, Maastricht, IGVG 90–12Google Scholar
  34. 34.
    De Vries G, de Waard D, Brookhuis KA (1989) A double blind study to compare the acute and subchronic effects of ebastine 10, 20, 30 mg o.d., triprolidine 10 mg o.d. and placebo on car driving performance. Traffic Research Center University of Groningen, GroningenGoogle Scholar
  35. 35.
    Riedel WJ, Schoenmakers EAJM, O’Hanlon JF (1989) Sedation and performance impairment with antihistamines. In: MA Kalinger (ed): Management of allergy in the 1990s. Hans Huber, Toronto, 38–49Google Scholar
  36. 36.
    Theunissen EL, Vermeeren A, van Oers ACM, van Maris I, Ramaekers JG (2004) A dose ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clinical and Experimental Allergy 34: 250–258PubMedCrossRefGoogle Scholar
  37. 37.
    Theunissen EL, Vermeeren A, Ramaekers JG (2006) Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. British Journal of Clinical Pharmacology 61: 79–86PubMedCrossRefGoogle Scholar
  38. 38.
    Ramaekers JG, Uiterwijk MM, O’Hanlon JF (1992) Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. European Journal of Clinical Pharmacology 42: 363–369PubMedGoogle Scholar
  39. 39.
    Taglialatela M, Timmerman H, Annuziato L (2000) Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends-in-pharmacological-sciences 21: 52–56PubMedCrossRefGoogle Scholar
  40. 40.
    O’Hanlon JF, Ramaekers JG (1995) Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 50: 234–342PubMedCrossRefGoogle Scholar
  41. 41.
    Verster JC, Volkerts ER, van Oosterwijck AW, Aarab M, Bijtjes SI, De Weert AM, Eijken EJ, Verbaten MN (2003) Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. Journal of Allergy and Clinical Immunology 111: 623–627PubMedCrossRefGoogle Scholar
  42. 42.
    Louwerens JW, Gloerich ABM, de Vries G, Brookhuis KA, O’Hanlon JF (1987) The relationship between driver’s blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: PC Noordzij, R Roszbach (eds.) International congress on alcohol, drugs and traffic safety, T 86. Exerpta Medica, Amsterdam, 183–186Google Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Eef Lien Theunissen
    • 1
  • Annemiek Vermeeren
    • 1
  • Eric F. P. M. Vuurman
    • 1
  • Johannes G. Ramaekers
    • 1
  1. 1.Neuropsychology and Psychopharmacology, Faculty of Psychology and NeuroscienceUniversity of MaastrichtMaastrichtThe Netherlands

Personalised recommendations